GLYC Stock Summary and Trading Ideas (Glycomimetics | NASDAQ:GLYC)

GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.

Glycomimetics trades on the NASDAQ stock market under the symbol GLYC.

As of April 25, 2024, GLYC stock price declined to $1.72 with 186,367 million shares trading.

GLYC has a beta of 2.42, meaning it tends to be more sensitive to market movements. GLYC has a correlation of 0.17 to the broad based SPY ETF.

GLYC has a market cap of $110.76 million. This is considered a Micro Cap stock.

In the last 3 years, GLYC stock traded as high as $4.16 and as low as $.51.

The top ETF exchange traded funds that GLYC belongs to (by Net Assets): VTI, VXF, IWC, AVSC, DFAC.

GLYC has outperformed the market in the last year with a return of +22.9%, while the SPY ETF gained +22.7%. However, in the most recent history, GLYC shares have underperformed the stock market with its stock returning -44.0% in the last 3 month period and -29.8% for the last 2 week period, while SPY has returned +3.3% and -2.8%, respectively.

GLYC support price is $1.73 and resistance is $1.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GLYC stock will trade within this expected range on the day.